Altri, SGPS, S.A. (ELI:ALTR)

Inozyme Pharma Revenue

Altri, SGPS had revenue of 184.12M EUR in the quarter ending June 30, 2025, a decrease of -23.01%. This brings the company's revenue in the last twelve months to 748.20M, down -6.97% year-over-year. In the year 2024, Altri, SGPS had annual revenue of 837.90M with 11.36% growth.

• Revenue (ttm): 748.20M
• Revenue Growth: -6.97%
• P/S Ratio: 1.43
• Revenue / Employee: 921.43K
• Employees: 812
• Market Cap: 1.07B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	837.90M	85.47M	11.36%
Dec 31, 2023	752.43M	-299.48M	-28.47%
Dec 31, 2022	1.05B	266.68M	33.96%
Dec 31, 2021	785.22M	217.59M	38.33%
Dec 31, 2020	567.62M	-167.91M	-22.83%